Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2009

View Archived Issues

Bevacizumab shows efficacy in patients with alkylator-refractory anaplastic astrocytoma

Phase I trial of EC-0489 for refractory or metastatic solid tumors begins

Schering-Plough reviews first quarter activities

siRNA-based therapy for pachyonychia congenita shows promise in phase Ib trial

Synthetic peptide ACT-1 enhances corneal wound healing in rats

Triamcinolone affects biomarkers of axonal damage and glial activity in MS patients

MacuSight's proprietary sirolimus ocular formulation shows promising pharmacokinetic profile

FDA approves Nerviano's IND to initiate phase I clinical trial of cancer drug PLK-1

Alkermes commences new ALKS-33 trials

Merck KGaA presents novel TGF-beta inhibitors for cancer treatment

Taiho claims novel retinoid RARalpha agonists as antitumor agents

Azor receives FDA approval as first-line high blood pressure treatment

Sanofi-aventis claims histamine H3 receptor inverse agonists for the treatment of sleep disorders

Takeda discloses retinol binding protein 4 lowering agents for the treatment of diabetes

Novel Na+/K+-ATPase inhibitors presented by Sigma-Tau for heart failure and hypertension

Data on MedImmune anticancer monoclonal antibodies MEDI-573, MEDI-3617 presented

LiPlasome describes activity of liposomal formulations of cisplatin, oxaliplatin

Cellerant Therapeutics doses first patient in a phase I CLT-008 trial

Nerviano Medical Sciences discloses novel anticancer agents under preclinical evaluation

Addrenex expands pipeline by licensing new drug to treat narcolepsy

Vivus announces the initiation of an open-label safety study for avanafil in ED

OSI provides update on diabetes and obesity programs

NIAID awards Dynavax 2-year grant for TLR inhibitors in skin diseases

Pozen to file NDA with the FDA for antiinflammatory drug PN-400 in mid-2009

The Medicines Company discontinues phase III CHAMPION clinical trials of cangrelor

FDA approves UCB's pegylated anti-TNF Cimzia for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...